Published in J Antimicrob Chemother on December 19, 2003
Real-time PCR in clinical microbiology: applications for routine laboratory testing. Clin Microbiol Rev (2006) 6.03
Overexpression of Candida albicans CDR1, CDR2, or MDR1 does not produce significant changes in echinocandin susceptibility. Antimicrob Agents Chemother (2006) 1.25
T-2307 shows efficacy in a murine model of Candida glabrata infection despite in vitro trailing growth phenomena. Antimicrob Agents Chemother (2010) 0.97
Rapid detection and sequence-specific differentiation of extended-spectrum beta-lactamase GES-2 from Pseudomonas aeruginosa by use of a real-time PCR assay. Antimicrob Agents Chemother (2004) 0.93
Contribution of clinically derived mutations in ERG11 to azole resistance in Candida albicans. Antimicrob Agents Chemother (2014) 0.92
Correlation between azole susceptibilities, genotypes, and ERG11 mutations in Candida albicans isolates associated with vulvovaginal candidiasis in China. Antimicrob Agents Chemother (2010) 0.87
The widely used ATB FUNGUS 3 automated readings in China and its misleading high MICs of Candida spp. to azoles: challenges for developing countries' clinical microbiology labs. PLoS One (2014) 0.84
Stepwise emergence of azole, echinocandin and amphotericin B multidrug resistance in vivo in Candida albicans orchestrated by multiple genetic alterations. J Antimicrob Chemother (2015) 0.83
Comparison of human and soil Candida tropicalis isolates with reduced susceptibility to fluconazole. PLoS One (2012) 0.82
Amino acid substitutions at the major insertion loop of Candida albicans sterol 14alpha-demethylase are involved in fluconazole resistance. PLoS One (2011) 0.81
Rapid detection of ERG11 gene mutations in clinical Candida albicans isolates with reduced susceptibility to fluconazole by rolling circle amplification and DNA sequencing. BMC Microbiol (2009) 0.78
High Virulence and Antifungal Resistance in Clinical Strains of Candida albicans. Can J Infect Dis Med Microbiol (2016) 0.75
Novel hydroxamates potentiated in vitro activity of fluconazole against Candida albicans. J Nat Sci Biol Med (2017) 0.75
In Vitro Susceptibility and Trailing Growth Effect of Clinical Isolates of Candida Species to Azole Drugs. Jundishapur J Microbiol (2016) 0.75
The Etest performed directly on blood culture bottles is a reliable tool for detection of fluconazole-resistant Candida albicans isolates. Antimicrob Agents Chemother (2017) 0.75
Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species. J Clin Microbiol (2004) 4.70
Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program. J Clin Microbiol (2004) 4.51
Differential vulnerability of anterior white matter in nondemented aging with minimal acceleration in dementia of the Alzheimer type: evidence from diffusion tensor imaging. Cereb Cortex (2004) 3.87
Epidemiology and predictors of mortality in cases of Candida bloodstream infection: results from population-based surveillance, barcelona, Spain, from 2002 to 2003. J Clin Microbiol (2005) 3.41
Comparative evaluation of NCCLS M27-A and EUCAST broth microdilution procedures for antifungal susceptibility testing of candida species. Antimicrob Agents Chemother (2002) 2.26
Comparison of visual and spectrophotometric methods of broth microdilution MIC end point determination and evaluation of a sterol quantitation method for in vitro susceptibility testing of fluconazole and itraconazole against trailing and nontrailing Candida isolates. Antimicrob Agents Chemother (2002) 2.20
In vitro susceptibilities of bloodstream isolates of Candida species to six antifungal agents: results from a population-based active surveillance programme, Barcelona, Spain, 2002-2003. J Antimicrob Chemother (2004) 1.88
Assessment of ribosomal large-subunit D1-D2, internal transcribed spacer 1, and internal transcribed spacer 2 regions as targets for molecular identification of medically important Aspergillus species. J Clin Microbiol (2005) 1.86
Epidemiologic and molecular characterization of an outbreak of Candida parapsilosis bloodstream infections in a community hospital. J Clin Microbiol (2004) 1.66
In vitro evolution of itraconazole resistance in Aspergillus fumigatus involves multiple mechanisms of resistance. Antimicrob Agents Chemother (2004) 1.62
An epidemic of coccidioidomycosis in Arizona associated with climatic changes, 1998-2001. J Infect Dis (2005) 1.60
Rapid acquisition of stable azole resistance by Candida glabrata isolates obtained before the clinical introduction of fluconazole. Antimicrob Agents Chemother (2005) 1.52
Candida parapsilosis characterization in an outbreak setting. Emerg Infect Dis (2004) 1.51
Histoplasmosis associated with exploring a bat-inhabited cave in Costa Rica, 1998-1999. Am J Trop Med Hyg (2004) 1.47
Evaluation of amphotericin B interpretive breakpoints for Candida bloodstream isolates by correlation with therapeutic outcome. Antimicrob Agents Chemother (2006) 1.37
Paradoxical growth effect of caspofungin observed on biofilms and planktonic cells of five different Candida species. Antimicrob Agents Chemother (2007) 1.33
Resolution of discrepant results for Candida species identification by using DNA probes. J Clin Microbiol (2004) 1.21
Over half of breakpoints in gene pairs involved in cancer-specific recurrent translocations are mapped to human chromosomal fragile sites. BMC Genomics (2009) 1.17
Stability of allelic frequencies and distributions of Candida albicans microsatellite loci from U.S. population-based surveillance isolates. J Clin Microbiol (2003) 1.09
Biofilm production and evaluation of antifungal susceptibility amongst clinical Candida spp. isolates, including strains of the Candida parapsilosis complex. Med Mycol (2010) 1.06
Fungal infections among returning travelers. Clin Infect Dis (2002) 1.03
Candidemia in neonatal intensive care units: Barcelona, Spain. Pediatr Infect Dis J (2006) 0.99
Epidemiology of community-onset candidemia in Connecticut and Maryland. Clin Infect Dis (2006) 0.93
Multilaboratory testing of antifungal combinations against a quality control isolate of Candida krusei. Antimicrob Agents Chemother (2008) 0.92
Coccidioidomycosis among workers at an archeological site, northeastern Utah. Emerg Infect Dis (2004) 0.92
A large outbreak of histoplasmosis among American travelers associated with a hotel in Acapulco, Mexico, spring 2001. Am J Trop Med Hyg (2003) 0.91
Effect of serum and surface characteristics on Candida albicans biofilm formation. Mycoses (2010) 0.88
Comparison of multilocus sequence typing and Ca3 fingerprinting for molecular subtyping epidemiologically-related clinical isolates of Candida albicans. Med Mycol (2006) 0.87
Outbreak of invasive aspergillosis among renal transplant recipients. Transplantation (2003) 0.87
Purifying selection, sequence composition, and context-specific indel mutations shape intraspecific variation in a bacterial endosymbiont. Genome Biol Evol (2011) 0.85
Persistence of oropharyngeal Candida albicans strains with reduced susceptibilities to fluconazole among human immunodeficiency virus-seropositive children and adults in a long-term care facility. J Clin Microbiol (2003) 0.85
Genome analysis of a simultaneously predatory and prey-independent, novel Bdellovibrio bacteriovorus from the River Tiber, supports in silico predictions of both ancient and recent lateral gene transfer from diverse bacteria. BMC Genomics (2012) 0.82
A large histoplasmosis outbreak among high school students in Indiana, 2001. Pediatr Infect Dis J (2004) 0.82
Rapid quantification of drug resistance gene expression in Candida albicans by reverse transcriptase LightCycler PCR and fluorescent probe hybridization. J Clin Microbiol (2004) 0.81
Evolving strategies in the management of aspergillosis. Expert Opin Pharmacother (2008) 0.81
Fungemia caused by Zygoascus hellenicus in an allogeneic stem cell transplant recipient. J Clin Microbiol (2004) 0.77
Molecular epidemiology of Candida parapsilosis sepsis from outbreak investigations in neonatal intensive care units. Infect Genet Evol (2008) 0.77